• PMH6 HEALTH EFFECTS AND HEALTH CARE RESOURCE UTILIZATION IN POLISH SCHIZOPHRENIC OUTPATIENTS INITIATING OR CHANGING TO OLANZAPINE OR TYPICAL ANTIPSYCHOTIC MONOTHERAPY- ANALYSIS OF 12-MONTH DATA FROM SOHO STUDY

    Nov 1, 2004, 00:00

  • PHP16 PHARMACOECONOMICS INTRODUCTION IN THE CREATION OF POSITIVE DRUG LIST IN BULGARIA

    Nov 1, 2004, 00:00

  • PHP17 MEDICINAL CANNABIS IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PDB3 COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR COMPARED TO NPH INSULIN IN PATIENTS WITH TYPE-2 DIABETES IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • CS2 COST-EFFECTIVENESS OF COMPETING ANTIPSYCHOTIC MONOTHERAPIES IN ACUTE BIPOLAR MANIA IN THE U.K.

    Nov 1, 2004, 00:00

  • POB1 OBESITYANDTHE RISK OF UPPER RESPIRATORY TRACT INFECTIONS

    Nov 1, 2004, 00:00

  • PCNI4 ALCEA (ADVANCED LUNG CANCER ECONOMIC ASSESSMENT)

    Nov 1, 2004, 00:00

  • QL3 QUALITY OF LIFE OF GASTROESOPHAGEL REFLUX DISEASE PATIENTS

    Nov 1, 2004, 00:00

  • PES14 RESPONSIVENESS OF SELF-REPORTED VISUAL FUNCTIONING IN AGE-RELATED MACULAR DEGENERATION (AMD) PATIENTS TO GENERAL HEALTH AND CHANGES IN VISUAL ACUITY IN A PHASE I/II RANDOMIZED CONTROLLED TRIAL OF LUCENTISTM (RANIBIZUMAB; RHUFAB V2)

    Nov 1, 2004, 00:00

  • PCV29 COST-EFFECTIVENESS OF REDUCTION IN CARDIOVASCULAR OUTCOMES WITH ATORVASTATIN IN PATIENTS WITH NORMAL TO MILDLY ELEVATED CHOLESTEROL LEVELS.TREATED FOR HYPERTENSION- THE ASCOT-LLA STUDY

    Nov 1, 2004, 00:00

  • PUK11 COST-CONSEQUENCES OF TREATING WOMEN WITH STRESS URINARY INCONTINENCE WITH DULOXETINE FROM THE PERSPECTIVE OF THE STATUTORY HEALTH INSURANCE IN GERMANY

    Nov 1, 2004, 00:00

  • PHP23 ANALYSIS OF CLINICAL INTERVENTION DOCUMENTATION BY PHARMACISTS

    Nov 1, 2004, 00:00

  • PCV79 THE COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN CHINA

    Nov 1, 2004, 00:00

  • PAR8 HEALTH ECONOMIC EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA) TREATED WITH ADALIMUMAB

    Nov 1, 2004, 00:00

  • PBR3 ECONOMIC MODELING OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHFPFM)- VALUE OF POTENTIAL VIRAL TRANSMISSION REDUCTION DUE TO PLASMA/ALBUMIN-FREE FORMULATION

    Nov 1, 2004, 00:00

  • PDB24 CONTINGENT VALUATION OF AN INHALED DELIVERY SYSTEM FOR INSULIN

    Nov 1, 2004, 00:00

  • PMH13 THE COST-EFFECTIVENESS OF PAROXETINE IN TREATMENT OF MAJOR DEPRESSIVE DISORDER IN JAPAN

    Nov 1, 2004, 00:00

  • PMC23 REVIEW AND ASSESSMENT OF THE ECONOMIC EVALUATION STUDIES ON HEALTH CARE IN MEXICO

    Nov 1, 2004, 00:00

  • PDB23 COST-EFFECTIVENESS OF ACARBOSE FOR THE MANAGEMENT OF IMPAIRED GLUCOSE TOLERANCE IN SWEDEN

    Nov 1, 2004, 00:00

  • PCV38 COSTS OF MYOCARDIAL INFARCTION TREATMENT IN RUSSIAN FEDERATION

    Nov 1, 2004, 00:00

  • DB2 LABOR MARKET EFFECTS OF INSULIN DEPENDENT AND NON-INSULIN DEPENDENT DIABETES AMONG CANADIAN LABOR FORCE

    Nov 1, 2004, 00:00

  • PCV60 TREATMENT OF NEWLY-DIAGNOSED HYPERTENSIVE PATIENTS IN ITALYA RETROSPECTIVE COHORT STUDY IN PRIMARY CARE

    Nov 1, 2004, 00:00

  • IN2 IS PROVISION OF ANTI-VIRAL INFLUENZA TREATMENT A SOUND INVESTMENT FOR PRIVATE AND PUBLIC EMPLOYERS IN THE UK?

    Nov 1, 2004, 00:00

  • PGI2 THE ECONOMIC EVALUATION OF A RANDOMIZED TRIAL COMPARING 'TEST-AND-TREAT' WITH PROMPT ENDOSCOPY IN PRIMARY CARE; THE HEALTH ECONOMICS OF THE SENSE-STUDY

    Nov 1, 2004, 00:00

  • PIN2 COST-EFFECTIVENESS OF LINEZOLID VERSUS VANCOMYCIN IN SUSPECTED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS IN NOSOCOMIAL PNEUMONIA IN GERMANY

    Nov 1, 2004, 00:00

  • PMC5 ARE THE BEST AVAILABLE, MOST APPLICABLE CLINICAL EFFECTIVENESS DATA USED IN ECONOMIC EVALUATIONS OF DRUG THERAPIES?

    Nov 1, 2004, 00:00

  • PES3 ANALYSIS OF CLINICAL EFFICACY OF LATANOPROST VS. THE MOST FREQUENT TREATMENT PATTERN FOR PRIMARY OPEN ANGLE GLAUCOMA (POAG) AND OCULAR HYPERTENSION (OH) IN POLAND

    Nov 1, 2004, 00:00

  • PCV25 SMOKING CESSATION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE-A COST-EFFECTIVENESS ANALYSIS

    Nov 1, 2004, 00:00

  • PUK22 DERIVING UNIT COSTS FOR RESOURCE UTILISATION IN PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE)-AN OBSERVATIONAL STUDY IN 14 EUROPEAN COUNTRIES

    Nov 1, 2004, 00:00

  • PCN37 DIFFERENCES IN TREATMENT PRACTICE, RESPONSE RATES AND COST OF EPOETIN ALFA AND DARBEPOETIN ALFA TREATMENT FOR ANEMIC CANCER PATIENTS- A RETROSPECTIVE ANALYSIS FROM SWEDEN

    Nov 1, 2004, 00:00

  • PMH10 ECONOMIC ANALYSIS OF RISPERIDONE LONG-ACTING INJECTION IN NEW ZEALAND

    Nov 1, 2004, 00:00

  • PCV48 ARIAL FIBRILLATION HISTORY AND ATRIOVENTRICULAR BLOCK APPEARANCE IN PATIENTS WITH SINUS NODE DISEASE AND SINGLE CHAMBER ATRIAL PACEMAKER-IMPACT ON COST OF THERAPY

    Nov 1, 2004, 00:00

  • PHP21 QUALITY ASSESSMENT OF AN AMBULATORY CARE CLINIC BASED COLLABORATIVE CARE APPROACH FOR ACHIEVING THERAPEUTIC GOALS

    Nov 1, 2004, 00:00

  • PMC20 DEVELOPMENT OF A NUTRITION RELATED QUALITY OF LIFE SCALE IN CHILDREN

    Nov 1, 2004, 00:00

  • PPN2 RESOURCE UTILISATION OF PATIENTS WITH CHRONIC PAIN CONDITIONS BEFORE AND DURING TREATMENT WITH LONG-ACTING OPIOIDS IN GERMANY

    Nov 1, 2004, 00:00

  • MH1 INCREMENTAL COST-EFFECTIVENESS OF THREE CLASSES OF ANTI-DEPRESSANTS- RESULTS FROM A UK RANDOMISED TRIAL

    Nov 1, 2004, 00:00

  • PUK7 WHEN SHOULD ERYTHROPOIETIN (EPO) BE REPLACED BY PACKED RED BLOOD CELL TRANSFUSION (TR) IN HEMODIALYSIS (HD) PATIENTS?

    Nov 1, 2004, 00:00

  • PGI7 COST BENEFIT ANALYSIS OF TWO TREATMENTS FOR PATIENTS WITH CHOLEDOCHOLITHIASIS AND CHOLECYSTOLITHIASIS

    Nov 1, 2004, 00:00

  • PCV47 DECISION ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE

    Nov 1, 2004, 00:00

  • PCV50 CHRONIC VENOUS DISEASE- PATIENTS PROFILE

    Nov 1, 2004, 00:00

  • PCNI8 A COST COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY

    Nov 1, 2004, 00:00

  • PMC2 A FRAMEWORK FOR HANDLING UNCERTAINTY AND VARIABILITY IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMS

    Nov 1, 2004, 00:00

  • POS8 PERSISTENCE WITH BISPHOSPHONATE THERAPY AND THE IMPACT OF DOSING FREQUENCY IN PATIENTS WITH POSTMENOPAUSAL OSTEOPOROSIS

    Nov 1, 2004, 00:00

  • PCVI5 COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND LVH IN SPAIN- AN ECONOMIC EVALUATION BASED ON THE LIFE TRIAL

    Nov 1, 2004, 00:00

  • PCV68 POPULATION IMPACT OF LOSARTAN USE ON STROKE IN FRANCE

    Nov 1, 2004, 00:00

  • PMC14 PERSONAL DRUG UTILIZATION REPORT (PDUR)-A CONTRIBUTION TO COST REDUCTION AND PATIENT EMPOWERMENT

    Nov 1, 2004, 00:00

  • PMW5 INFERTILITY TREATMENT POLICIES IN GERMANY AND THE UNITED KINGDOM-WILLINGNESS TO PAY AMONG AFFECTED COUPLES

    Nov 1, 2004, 00:00

  • DB1 ASSOCIATION BETWEEN ANTIPSYCHOTIC DRUGS AND DIABETES MELLITUS- A PHARMO STUDY

    Nov 1, 2004, 00:00

  • PCN33 HEALTH UTILITY VALUES FOR CANCER RELATED ANAEMIA

    Nov 1, 2004, 00:00

  • MC6 PRODISQ A MODULAR QUESTIONNAIRE ON PRODUCTIVITY AND DISEASE FOR ECONOMIC EVALUATION STUDIES IN PATIENT SETTINGS AND ORGANISATIONAL SETTINGS

    Nov 1, 2004, 00:00

  • PPN8 RESPONSIVENESS OF THE SHUTTLE WALKING TEST COMPARED WITH DISEASE SPECIFIC AND GENERIC OUTCOME MEASURES IN PATIENTS WITH CHRONIC BACK PAIN

    Nov 1, 2004, 00:00

  • PAR5 MESSAGE- AN OBSERVATIONAL POST-LAUNCH STUDYTO ASSESS EFFECTIVENESS AND COST OF SUPLASYN IN PATIENTS WITH KNEE OSTEOARTHRITIS

    Nov 1, 2004, 00:00

  • PCV26 THE COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS FOLLOWING TOTAL HIP ARTHROPLASTY

    Nov 1, 2004, 00:00

  • PCN39 QUALITY ASSURANCE IN CANCER CHEMOTHERAPY THROUGH PHARMACEUTICAL CARE DOCUMENTATION

    Nov 1, 2004, 00:00

  • PC02 ITEM SELECTION FOR COPD-SPECIFIC UTILITY INSTRUMENT

    Nov 1, 2004, 00:00

  • PCV20 COST EFFECTIVENESS OF ANTIHYPERTENSIVE MONO-THERAPYWITH PERINDOPRIL OR ENALAPRIL IN ELDERLY PATIENTS FROM THE THIRD PARTY PAYER PERSPECTIVE

    Nov 1, 2004, 00:00

  • PGI5 COSTS BENEFITS WITH ESOMEPRAZOLE 20MG 'ONDEMAND' TREATMENT IN GASTROESOPHAGEAL REFLUX DISEASE (GERD) PATIENTS IN BELGIUM

    Nov 1, 2004, 00:00

  • PMH3 FOLLOW-UP OF SCHIZOPHRENIA PATIENTS DISCHARGED ON RISPERIDONE OR OLANZAPINE- A TIME-TO-EVENT ANALYSIS

    Nov 1, 2004, 00:00

  • CV3 NURSING HOME RESIDENTS WITH STROKE- CHANGES IN MANAGEMENT LEVELS AND COSTS OVER A SIX YEAR PERIOD

    Nov 1, 2004, 00:00

  • HP7 STRATEGIES OF PRIORIZATION BASED ON THE SOCIAL WELFARE FUNCTION

    Nov 1, 2004, 00:00

  • PCV39 MODELING THE ECONOMIC CONSEQUENCES OF IMPLANTING DUAL CHAMBER VS. SINGLE CHAMBER PACEMAKERS IN THE UK

    Nov 1, 2004, 00:00

  • PCN35 VALUATION OF SOCIETAL PREFERENCE BETWEEN THERAPIES FOR CANCER-RELATED ANAEMIA (CRA)- RECOMBINANT HUMAN ERYTHROPOETIN (RH-EPO) VERSUS BLOOD TRANSFUSION

    Nov 1, 2004, 00:00

  • PES11 ESTIMATION OF NATIONWIDE COSTS OF ANNUAL ASSISTANCE ATTRIBUTABLE TO VISUAL IMPAIRMENT, FROM AN ACTIVITY OF DAILY LIVING QUESTIONNAIRE

    Nov 1, 2004, 00:00

  • PMW3 IMPROVING THE DELIVERY OF CHILD AND MATERNAL HEALTH CARE IN A POOR SETTING- COSTS AND BARRIERS TO BE CONSIDERED IN THE IMPLEMENTATION OF WHO MOTHER-BABY PACKAGE IN MORELOS, MEXICO

    Nov 1, 2004, 00:00

  • PMH16 TOTAL HEALTH CARE CONSUMPTION AND COSTS OF SICKNESS FUND INSURED PATIENTS IN THE NETHERLANDS

    Nov 1, 2004, 00:00

  • POB3 EVALUATION OF THE COST-UTILITY OF ORLISTAT (XENICAL) IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PCV54 USE OF VISUAL ANALOGUE SCALE (VAS) AS A METHOD OF DISCRIMINATION FOR PHYSICAL DISABILITY SEVERITY IN STROKE

    Nov 1, 2004, 00:00

  • EE2 LIVING WITH A DERMATOSIS- A NATIONAL SURVEY OF DEPRESSIVE SYMPTOMATOLOGY IN BELGIUM

    Nov 1, 2004, 00:00

  • PHP38 USE OF PATIENT-REPORTED OUTCOMES IN EVALUATION OF HEART FAILURE DEVICE THERAPY- THE REGULATORY PERSPECTIVE

    Nov 1, 2004, 00:00

  • POB4 EVALUATING THE IMPACT OF WEIGHT LOSS ON QUALITY OF LIFE IN PATIENTS TAKING ORLISTAT AND ENROLLED IN THE MOTIVATION, ADVICE AND PRO-ACTIVE SUPPORT (MAP) PROGRAMME

    Nov 1, 2004, 00:00

  • PGI10 HEALTH RELATED QUALITY OF LIFE AMONG POLISH GASTROESOPHAGEAL REFLUX DISEASE PATIENTS

    Nov 1, 2004, 00:00

  • PCV37 ECONOMIC EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH INSURANCE (SHI) IN GERMANY

    Nov 1, 2004, 00:00

  • PMH9 A PROBABILISTIC COST-EFFECTIVENESS ANALYSIS OF ESCITALOPRAM, GENERIC CITALOPRAM AND VENLAFAXINE AS A FIRST-LINE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN THE UNITED KINGDOM

    Nov 1, 2004, 00:00

  • PPT1 COST-OF-ILLNESS STUDY IN ACROMEGALIC PATIENTS IN ITALY

    Nov 1, 2004, 00:00

  • PUK5 ECONOMIC VALUATION OF THE EFFECTS OF DIETARY PROTEIN RESTRICTION ON THE PROGRESSION OF CHRONIC RENAL DISEASE

    Nov 1, 2004, 00:00

  • PIN24 IMPROVEMENT IN PATIENT-REPORTED DEPRESSION IN HIV PATIENTS EXPERIENCING GRADE 2 SIDE EFFECTS AFTER SUBSTITUTION OF THEIR PROTEASE INHIBITOR (PI)/NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) WITH LOPINAVIR/RITONAVIR (LPV/R)

    Nov 1, 2004, 00:00

  • PHP6 PRESCRIPTION PATTERN OF ALIMENTARYTRACT DRUGS AFTER CHANGES OF DRUG BENEFIT STATUS IN KOREA

    Nov 1, 2004, 00:00

  • PBR2 ECONOMIC IMPACT OF ANTIHEMOPHILIC FACTOR (RECOMBINANT), PLASMA/ALBUMIN-FREE METHOD (RAHF-PFM) IN PATIENTS WITH HEMOPHILIA A

    Nov 1, 2004, 00:00

  • POS2 CLINICAL AND ECONOMIC IMPACT OF RISEDRONATE TREATMENT FOR POST-MENOPAUSAL OSTEOPOROSIS IN FRANCE

    Nov 1, 2004, 00:00

  • PC03 DEVELOPMENT OF A COPD SEVERITY SCORE IN CLAIMS DATABASE

    Nov 1, 2004, 00:00

  • PCN27 PATIENT PREFERENCE FORANASTROZOLE AS ADJUVANT HORMONAL THERAPY FOR EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE WILLINGNESS-TO-PAY (WTP) METHODOLOGY

    Nov 1, 2004, 00:00

  • PHP32 LOSS PROFILES DERIVED FROM ACTIVITY OF DAILY LIVING SCORES ATTRIBUTABLE TO HANDICAPS

    Nov 1, 2004, 00:00

  • PAA7 A COMPARISON OF TWO APPROACHES TO ESTIMATE ANNUAL MEDICATION COSTS IN THE KORA ASTHMA AND ALLERGY STUDY

    Nov 1, 2004, 00:00

  • MC8 COMPARING THE INTERVAL PROPERTIES OF HEALTH-STATE VALUATIONS MEASURED USING THE VISUAL ANALOGUE SCALE AND RANK-BASED SCALING

    Nov 1, 2004, 00:00

  • PIN19 A COMPARISON OF COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS) VERSUS INTERFERON ALFA-2B PLUS RIBAVIRIN AS FIRST TREATMENT OF CHRONIC HEPATITIS C IN THE UK

    Nov 1, 2004, 00:00

  • HP4 DRUG COSTS DEVELOPMENT AFTER PATENT EXPIRY IN THE THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PPN7 USE OF THE NEUROPATHIC PAIN SCALE IN AN INTERNATIONAL STUDY

    Nov 1, 2004, 00:00

  • PCV28 COST-EFFECTIVENESS OF RAMIPRIL IN PATIENTS AT HIGH RISK FOR CARDIOVASCULAR EVENTS- A SWISS PERSPECTIVE

    Nov 1, 2004, 00:00

  • PNL8 COST-EFFECTIVENESS OF THROMBOLYSIS WITH RT-PA FOR ACUTE ISCHEMIC STROKE IN TAIWAN

    Nov 1, 2004, 00:00

  • PDB20 COST AND OUTCOMES OF THE DIABETES CLINIC IN A COMMUNITY HOSPITAL, MAE HONG SON, THAILAND

    Nov 1, 2004, 00:00

  • PUK20 IMPLICATIONS OF OVERACTIVE BLADDER ICD-9 CODE CHANGES AND USE OF CODES IN A MANAGED CARE POPULATION

    Nov 1, 2004, 00:00

  • PHP25 WILLINGNESS TO PAY VERSUS OUT OF POCKET PAYMENTS FOR HEALTH SERVICES UTILIZATION IN GREECE

    Nov 1, 2004, 00:00

  • PUK12 LONG-TERM COST-EFFECTIVENESS MODELLING OF FEEDBACK MICROWAVE THERMOTHERAPY VERSUS DRUG TREATMENT IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA AND LOWER URINARY TRACT SYMPTOMS

    Nov 1, 2004, 00:00

  • PHP14 ECONOMIC ASPECTS OF INDIVIDUAL TREATMENT IN POLAND-OUT-PATIENT VIEWPOINT

    Nov 1, 2004, 00:00

  • MC1 COMPLIANCE, ADHERENCE, AND PERSISTENCE- A COMPARISON OF THREE METHODOLOGIES FOR EVALUATING PATIENT COMPLIANCE USING PRESCRIPTION CLAIMS DATA

    Nov 1, 2004, 00:00

  • PCNI5 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT2)- A PATIENT-LEVEL COST COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN FRANCE

    Nov 1, 2004, 00:00

  • PNL16 A COMPARATIVE STUDY ON RESOURCE USE, COSTS AND CAREGIVER BURDEN BETWEEN RASAGILINE AND ENTACAPONE IN FLUCTUATING PARKINSONS DISEASE (PD) PATIENTS

    Nov 1, 2004, 00:00

  • PAR3 QUANTIFYING DISEASE SEVERITY AS A DETERMINANT OF COSTS AND QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN AUSTRALIA

    Nov 1, 2004, 00:00

  • PCN4 COST-UTILITY ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER

    Nov 1, 2004, 00:00

  • PCV4 FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION

    Nov 1, 2004, 00:00

  • PAA5 A COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS OF FLUTICASONE AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA

    Nov 1, 2004, 00:00

  • PIN29 ECONOMIC EVALUATION OF MENINGOCOCCAL C VACCINATION PROGRAMMES AND ITS IMPACT ON DECISION MAKING

    Nov 1, 2004, 00:00

  • PCV41 COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF HYPERCHOLESTEROLEMIA IN CATALONIA, SPAIN

    Nov 1, 2004, 00:00

  • PNL21 INDEPENDENT EFFECT OF DYSKINESIA ON HEALTHRELATED QUALITY OF LIFE IN PATIENTS WITH PARKINSONS DISEASE-A MULTIVARIATE ANALYSIS

    Nov 1, 2004, 00:00

  • PNL20 A SIMPLIFIED SEVERITY SCALE FOR THE ASSESSMENT OF RESTLESS LEGS SYNDROME- THE DESYR STUDY GROUP

    Nov 1, 2004, 00:00

  • PHP31 SENSIBLE FLEXIBILITY OR UNNECESSARY DUPLICATION] THE USE OF DECISION MODELLING IN NICE APPRAISALS

    Nov 1, 2004, 00:00

  • PDB27 A MULTIDIMENSIONAL HEALTH CARE INTERVENTION ASSESSMENT- THE CO-ORDINATED DIABETES HEALTHCARE NETWORK

    Nov 1, 2004, 00:00

  • PCNI3 COST-EFFECTIVENESS ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH CISPLATIN-ETOPOSIDE, CISPLATIN-WINORELBINE AND CISPLATIN-GEMCYTABINE

    Nov 1, 2004, 00:00

  • PNL15 RETROSPECTIVE EVALUATION OF THE DOSE OF DYSPORT IN THE CLINICAL MANAGEMENT OF CERVICAL DYSTONIA OR BLEPHAROSPASM-THE REAL DOSE STUDY EXPANSION-COST CONSIDERATIONS BASED ON DRUG START

    Nov 1, 2004, 00:00

  • PPN10 QUANTIFICATION OF SUSPECTED ADDICTION TREATMENT OF NARCOTIC ANALGESICS USING PRESCRIPTION SEQUENCE ANALYSIS- EXPERIENCE OF A STATE-BASED WORKERS COMPENSATION SYSTEM

    Nov 1, 2004, 00:00

  • PAR28 ASSESSING INTANGIBLES IN BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS (RA). A WILLINGNESS TO PAY (WTP) STUDY IN SPANISH PATIENTS

    Nov 1, 2004, 00:00

  • PMH2 GEO OBSERVATIONAL STUDY- 12 MONTHS DISEASE CHARACTERISTICS, SIDE EFFECTS AND SOCIOECONOMIC STATUS IN SCHIZOPHRENIA PATIENTS TREATED WITH OLANZAPINE AND HALOPERIDOL IN GERMANY

    Nov 1, 2004, 00:00

  • PCN45 MODELING EFFECT IN PHARMACOECONOMICS ANALYSIS USING ARTIFICIAL NEURAL NETWORKS

    Nov 1, 2004, 00:00

  • CV8 PHARMACOECONOMIC CONSEQUENCES OF PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES IN THE CZECH REPUBLIC

    Nov 1, 2004, 00:00

  • PES19 SENSITIVE SKIN- QUALITY OF LIFE IMPACT

    Nov 1, 2004, 00:00

  • UC3 A FIVE-LEVEL VERSION OF EQ-5D

    Nov 1, 2004, 00:00

  • PRS3 PHARMACOECONOMY AND ANTIBIOTIC TREATMENT WITHIN THE SLOVAK REPUBLIC

    Nov 1, 2004, 00:00

  • PAA3 RESOURCE USE IN PATIENTS WITH EXACERBATIONS OF ASTHMA WITH DIFFERENT UNDERLYING DEGREES OF SEVERITY IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2004, 00:00

  • PAA8 COST ESTIMATION IN CLINICAL PIGGY-BACK STUDIES WITH DISCONTINUATIONS-COMPARISON OF DIFFERENT APPROACHES

    Nov 1, 2004, 00:00

  • PCV67 USE OF CLOPIDOGREL AFTER ISCHEMIC VASCULAR EVENTS IN THE THE NETHERLANDS

    Nov 1, 2004, 00:00

  • PNL13 PROFILE OF PATIENTS SUFFERING FROM RESTLESS LEGS SYNDROME AND ESTIMATION OF THEIR ANNUAL COST IN AN AMBULATORY CARE SETTING, IN FRANCE

    Nov 1, 2004, 00:00

  • PNL5 SOCIAL COSTS OF PARKINSON DISEASE IN ITALY

    Nov 1, 2004, 00:00

  • PDB8 WILL IRBESARTAN LEAD TO COST SAVINGS DUE TO DELAYED END STAGE RENAL DISEASE IN HYPERTENSIVE TYPE-2 DIABETICS IN GERMANY?

    Nov 1, 2004, 00:00

  • PES7 A PHARMACOECONOMIC ANALYSIS OF THE FIXED COMBINATION LATANOPROST/TIMOLOL VERSUS DORZOLAMIDE/TIMOLOL IN THE TREATMENT OF PATIENTS WITH GLAUCOMA IN SPAIN

    Nov 1, 2004, 00:00

  • PCV32 SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE STAGE NYHA II WITH CRATAEGUS EXTRACT WS 1442-A PROSPECTIVE 3-YEAR PHARMACOECONOMIC STUDY

    Nov 1, 2004, 00:00

  • EE4 COMPARING TREATMENT COSTS ASSOCIATED WITH SCREENING FOR GLAUCOMAVS NOT SCREENING- EVALUATING THE ECONOMIC IMPACT OF THE NEW HEDIS MEASURE

    Nov 1, 2004, 00:00

  • PCN24 GEMZAR RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIAL (GREAT) IN THE TREATMENT OF NON-SMALL-CELL LUNG CANCER IN TAIWAN

    Nov 1, 2004, 00:00

  • QL8 DEVELOPMENT AND VALIDATION OF THE DIAPASON- A TREATMENT SATISFACTION QUESTIONNAIRE FOR INDIVIDUALS WITH TYPE-2 DIABETES

    Nov 1, 2004, 00:00

  • PCV70 DECISION ANALYSIS AND COSTS OF LOW MOLECULAR WEIGHT HEPARINS- A CASE STUDY IN FRANCE

    Nov 1, 2004, 00:00

  • QL6 THE BARTHEL PREFERENCE INDEX (BPI)- A NEW CONDITION-SPECIFIC PREFERENCE INDEX (COPI) FOR USE IN STROKE

    Nov 1, 2004, 00:00

  • PCNIO COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER DIAGNOSIS WITH CAD (COMPUTER AIDED DETECTION)

    Nov 1, 2004, 00:00

  • PPN3 AN OBSERVATIONAL STUDY OF INTRAVENOUS PATIENTCONTROLLED ANALGESIA RESOURCE UTILIZATION AT AN ACADEMIC MEDICAL CENTER

    Nov 1, 2004, 00:00

  • IN3 ECONOMIC EVALUATION OF INTRAVENOUS ITRACONAZOLE IN PRESUMED SYSTEMIC FUNGAL INFECTIONS IN NEUTROPENIC PATIENTS IN GREECE

    Nov 1, 2004, 00:00

  • PMH27 THE EFFECT OF RAISING THREE TIER CO-PAYMENTS ON SSRI ANTIDEPRESSANT COMPLIANCE RATES

    Nov 1, 2004, 00:00

  • PNL7 COSTS OF STROKE UNIT CARE IN GERMANY

    Nov 1, 2004, 00:00

  • QL7 VALIDATION OF A PATIENT-ADMINISTERED QUESTIONNAIRE TO MEASURE THE SEVERITY OF LOWER URINARY TRACT SYMPTOMS IN UNCOMPLICATED URINARY TRACT INFECTION-THE UTI SYMPTOM ASSESSMENT (USA) QUESTIONNAIRE

    Nov 1, 2004, 00:00

  • PCNI COST-EFFECTIVENESS OF APREPITANT GIVEN WITH STANDARD ANTIEMETICS IN PATIENTS RECEIVING CHEMOTHERAPY IN OFFICE-BASED SETTINGS IN GERMANY

    Nov 1, 2004, 00:00

  • PES23 SUN SENSITIVITY AND PERSONAL BEHAVIOURS

    Nov 1, 2004, 00:00

  • PCVI4 AN ECONOMIC ANALYSIS OF CATHETER ABLATION FORTHE TREATMENT OF VENTRICULAR TACHYCARDIA

    Nov 1, 2004, 00:00

  • PHP7 THE IMPACT OF PHARMACEUTICAL MARKET COMPETITION ON PRICE AND REIMBURSEMENT STATUS OF PATENTED DRUGS IN THE NETHERLANDS, BELGIUM, FRANCE AND GERMANY

    Nov 1, 2004, 00:00

  • PMC22 REVIEW OF INSTRUMENTS MEASURING TREATMENT SATISFACTION WITH MEDICATION

    Nov 1, 2004, 00:00

  • PES12 NON-MEDICAL COSTS RELATED TO VISUAL IMPAIRMENT IN FOUR EUROPEAN COUNTRIES (FRANCE, GERMANY, ITALY AND THE UNITED KINGDOM)

    Nov 1, 2004, 00:00

  • DISCLOSURE INFORMATION

    Nov 1, 2004, 00:00

  • PCV77 ASSESSING THE LIKELIHOOD OF FRACTURE WITH ORAL ANTI-SPASTICITY MEDICATIONS- A CASE-CONTROL STUDY

    Nov 1, 2004, 00:00

  • PAR 17 LINGUISTIC ADAPTATION AND VALIDATION OF THE ARTHRITIS TREATMENT SATISFACTION QUESTIONNAIRE (ARTS) INTO SPANISH

    Nov 1, 2004, 00:00

  • PAR 16 CO-PAYMENTS IN RHEUMATOID ARTHRITIS OBSERVED IN A GERMAN COHORT

    Nov 1, 2004, 00:00

  • Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders- A Markov Model

    Sep 1, 2004, 00:00

  • Publication of Pharmacoeconomic Data Submitted to Reimbursement or Clinical Guidelines Agencies

    Sep 1, 2004, 00:00

  • Medical Care Costs Associated with Postmenopausal Estrogen Plus Progestogen Therapy

    Sep 1, 2004, 00:00

  • Dermatological Applications of Needs-Based Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Technology, Regulations, and Value in Health

    Sep 1, 2004, 00:00

  • Requirements for Quality of Life Instruments in Clinical Research

    Sep 1, 2004, 00:00

  • Effectiveness of Needs-Based Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Estimating Survival for Cost-Effectiveness Analyses- A Case Study in Atherothrombosis

    Sep 1, 2004, 00:00

  • Adapting Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Defining Patient-Reported Outcomes

    Sep 1, 2004, 00:00

  • Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple Sclerosis

    Sep 1, 2004, 00:00

  • Integrating Patient-Reported Outcomes

    Sep 1, 2004, 00:00

  • The Needs-Based Approach to Quality of Life Assessment

    Sep 1, 2004, 00:00

  • Comparison of the HUI3 with the SF-36 Preference Based SF-6D in a Clinical Trial Setting

    Sep 1, 2004, 00:00

  • Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making- How Are Cost-Effectiveness Thresholds Expected to Emerge?

    Sep 1, 2004, 00:00

  • Development of Needs-Based Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Comparing Medications in a Therapeutic Area Using an NNT Model

    Sep 1, 2004, 00:00

  • Portfolio Theory and Cost-Effectiveness Analysis- A Further Discussion

    Sep 1, 2004, 00:00

  • Summary of Needs-Based Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Use of Outcomes Research in Assuring Patient Safety and Quality Care, Second Plenary Session, ISPOR 8th Annual International Meeting, Arlington, VA, USA

    Sep 1, 2004, 00:00

  • Application of Rasch Analysis in the Development and Application of Quality of Life Instruments

    Sep 1, 2004, 00:00

  • Systematic Assessment of Decision Models in Parkinson's Disease

    Sep 1, 2004, 00:00

  • Return on Investment of Different Combinations of Bupropion SR Dose and Behavioral Treatment for Smoking Cessation in a Health Care Setting- An Employer's Perspective

    Sep 1, 2004, 00:00

  • Cost-Effectiveness Analysis of Bicalutamide (Casodex™)* * Casodex™ is a registered trademark for AstraZeneca.for Adjuvant Treatment of Early Prostate Cancer

    Jul 1, 2004, 00:00

  • Cost–Utility of Adjuvant High-Dose Interferon Alpha Therapy in Stage III Cutaneous Melanoma in Quebec

    Jul 1, 2004, 00:00

  • Patient Preference and Willingness-to-Pay for Humalog Mix25 Relative to Humulin 30/70- A Multicountry Application of a Discrete Choice Experiment

    Jul 1, 2004, 00:00

  • Response to Concerns Regarding the ISPOR Code of Ethics for Researchers

    Jul 1, 2004, 00:00

  • Costs and Benefits of Influenza Vaccination and Work Productivity in a Colombian Company from the Employer's Perspective

    Jul 1, 2004, 00:00

  • Erratum

    Jul 1, 2004, 00:00

  • The Economic Impact of Payer Policies after the Rx-to-OTC Switch of Second-Generation Antihistamines

    Jul 1, 2004, 00:00

  • Concerns Regarding the ISPOR Code of Ethics for Researchers

    Jul 1, 2004, 00:00

  • Cost-Effectiveness of Low-Level Heat Wrap Therapy for Low Back Pain

    Jul 1, 2004, 00:00

  • Discounting Health Outcomes in Economic Evaluation- The Ongoing Debate

    Jul 1, 2004, 00:00

  • In Memoriam- Bernie O'Brien (1959–2004)

    Jul 1, 2004, 00:00

  • Impact of Anemia on Hospitalization Time, Charges, and Mortality in Patients with Heart Failure

    Jul 1, 2004, 00:00

  • The Construct and Concurrent Validity of the EQ-5D in a Renal Transplant Population

    Jul 1, 2004, 00:00

  • The Impact of Urinary Urgency and Frequency on Health-Related Quality of Life in Overactive Bladder- Results from a National Community Survey

    Jul 1, 2004, 00:00

  • Development of a Parametric Simulation Model for Forecasting Goal-Oriented Treatment Outcomes

    Jul 1, 2004, 00:00

  • Estimating a Preference-Based Single Index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) Instrument from the SF-6D

    Jul 1, 2004, 00:00

  • PMH44 REMISSION OF PSYCHOTIC SYMPTOMS AND LONG-TERM FUNCTIONAL OUTCOMES IN THE TREATMENT OF SCHIZOPHRENIA IN USUAL CARE

    May 1, 2004, 00:00

  • PAA17 THE ASSOCIATION BETWEEN ADHERENCE, ASTHMA CONTROL, GENERIC AND DISEASE SPECIFIC QUALITY OF LIFE INSTRUMENTS IN ASTHMA

    May 1, 2004, 00:00

  • PMH1 EFFECT OF ZIPRASIDONE INITIAL DOSING ON DISCONTINUATION IN SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PMH72 MEDICATION PRESCRIBING PATTERNS FOR PATIENTS WITH BIPOLAR DEPRESSION

    May 1, 2004, 00:00

  • PCV19 GENDER AND STATIN THERAPY COST AND EFFICACY

    May 1, 2004, 00:00

  • PMD5 TRACING THE DIFFUSION OF COST-UTILITY ANALYSIS AS AN INNOVATION

    May 1, 2004, 00:00

  • PBR6 REPORT FROM THE FIRST MULTIDISCIPLINARY COST OF BLOOD CONSENSUS (COBCON) WORKING GROUP TO ESTABLISH STANDARD METHODOLOGY

    May 1, 2004, 00:00

  • PDB3 EVALUATION OF PHARMACIST INTERVENTIONS IN DIABETIC PATIENTS FROM RURAL COMMUNITY HEALTH CENTERS

    May 1, 2004, 00:00

  • PCV17 A COST-UTILITY ANALYSIS OF LOSARTAN VERSUS ATENOLOL IN THE TREATMENT OF MILD TO MODERATE HYPERTENSION

    May 1, 2004, 00:00

  • PPN4 EXAMINATION OF TOTAL HEALTH CARE EXPENDITURES FOR PATIENTS ON LONG ACTING OPIOID MEDICATIONS FOR THE TREATMENT OF CHRONIC PAIN IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PMH57 THE EFFECT OF BEHAVIORAL CARVE-OUTS ON PHARMACEUTICAL USE AND EXPENDITURES

    May 1, 2004, 00:00

  • PHP1 A COST MINIMIZATION ANALYSIS OF FOMEPIZOLE VERSUS ETHANOL WITH OR WITHOUT HEMODIALYSIS IN THE ACUTE MANAGEMENT OF METHANOL OR ETHYLENE-GLYCOL POISONING

    May 1, 2004, 00:00

  • PHP23 PHARMACEUTICAL PRESCRIPTION- COSTS AND FACTORS OF INFLUENCE

    May 1, 2004, 00:00

  • PCN30 USING THE DIFFERENCE IN DIFFERENCE METHOD TO UNDERSTAND OUTCOMES IN PROSTATE CANCER

    May 1, 2004, 00:00

  • PMH36 THE COSTS OF POLY-PHARMACY, NON-DRUG TREATMENT, NUMBER OF DRUGS AND SWITCHING FOR BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PMH21 RELATIONSHIP BETWEEN QUETIAPINE DOSE AND LEVELS OF MENTAL HEALTH RESOURCE USE AMONG PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER

    May 1, 2004, 00:00

  • AR4 THE DEVELOPMENT OF PROPENSITY SCORES FROM ADMINISTRATIVE DATABASES FOR THE ANALYSIS OF THE EFFECTIVENESS OF AN OSTEOARTHRITIS ACADEMIC DETAILING SERVICE ON PRESCRIBING BEHAVIOUR

    May 1, 2004, 00:00

  • PMD21 A DESCRIPTIVE ANALYSIS TO INVESTIGATE THE DIFFERENCES BETWEEN TRADERS AND NON-TRADERS IN TIME TRADE OFF

    May 1, 2004, 00:00

  • MH1 AN ECONOMIC ANALYSIS OF ANTIPSYCHOTIC TREATMENT FOR SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PES18 THE IMPACT OF THE SYSTEM TO MANAGE ACCUTANERELATED TERATOGENICITYTM (SMARTTM) RISK MANAGEMENT PROGRAM ON ISOTRETINOIN PRESCRIBING TRENDS

    May 1, 2004, 00:00

  • PCV43 EVALUATION OF THE ASSOCIATION BETWEEN HEALTH-RELATED UTILITY AND OBESITY IN HOSPITAL TREATED SUBJECTS

    May 1, 2004, 00:00

  • PMH56 MENTAL HEALTH SERVICES AND DRUG UTILIZATION PATTERNS FOR STUDENTS WITH MENTAL ILLNESSES IN SCHOOL-BASED HEALTH CENTERS

    May 1, 2004, 00:00

  • PDB18 INCREASED HEALTH EXPENDITURES AMONG DIABETES PATIENTS ON INSULIN WITH HYPOGLYCEMIA

    May 1, 2004, 00:00

  • PIN3 OUTCOMES FOLLOWING THE USE OF AZITHROMYCIN OR CLARITHROMYCIN FOR RESPIRATORY TRACT INFECTIONS IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PCV55 DELAY IN DIAGNOSIS AS A FACTOR IN INITIATION OF TREATMENT FOR HYPERCHOLESTEROLAEMIA

    May 1, 2004, 00:00

  • PCV9 LIPID MANAGEMENT AND FACTORS AFFECTING GOAL ATTAINMENT IN LATIN AMERICA

    May 1, 2004, 00:00

  • PES5 THE COST-EFFECTIVENESS OF OTOTOPICAL CIPROFLOXACIN AND DEXAMETHASONE VERSUS OTOTOPICAL OFLOXACIN FOR THE TREATMENT OF OTORRHEA IN PATIENTS WITH TYMPANOSTOMY TUBES

    May 1, 2004, 00:00

  • OP4 DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED USEFULNESS SCALE TO EVALUATE ANTIEPILEPTIC PHARMACOTHERAPY IN PATIENTS WITH EPILEPSY

    May 1, 2004, 00:00

  • PNL24 DEVELOPING A COMPUTER ALGORITHM TO IDENTIFY EPILEPSY CASES IN MANAGED CARE ORGANIZATIONS AND ESTIMATE PREVALENCE, INCIDENCE, AND MORTALITY

    May 1, 2004, 00:00

  • PCV48 OBESITY AMONG HIGH SCHOOL STUDENT AND CONTRIBUTING FACTORS

    May 1, 2004, 00:00

  • PHP21 E-COMMERCE ON PHARMACEUTICALS- A POSITIVE TREND OR A TECHNOLOGICAL DEAMON?

    May 1, 2004, 00:00

  • PCV5 PREDICTORS OF ADHERENCE WITH CONCOMITANT ANTIHYPERTENSIVE AND LIPID-LOWERING THERAPY

    May 1, 2004, 00:00

  • PHP3 HANDGUN INJURIES TO CHILDREN AND TEENS RESULTING IN HOSPITALIZATION- CIRCUMSTANCES, RESOURCE USE AND COSTS

    May 1, 2004, 00:00

  • PNL8 TRIPTANS IN THE ACUTE TREATMENT OF MIGRAINE- COSTEFFECTIVENESS ANALYSIS BASED ON NUMBER NEEDED TO TREAT AND DOSES NEEDED TO TREAT

    May 1, 2004, 00:00

  • PMH59 ANTIPSYCHOTIC ADHERENCE AMONG CENTRAL TEXAS VETERANS

    May 1, 2004, 00:00

  • PIN19 THE COST-EFFECTIVENESS ANALYSIS OF COMBINATION OF PEGINTERFERON ALFA-2A AND RIBAVIRIN VERSUS COMBINATION OF PEGINTERFERON ALFA-2B AND RIBAVIRIN IN CHRONIC HEPATITIS C IN POLAND

    May 1, 2004, 00:00

  • PCV27 HOSPITALIZATION COSTS AND LENGTH OF STAY IN POST-MI PATIENTS WITH HEART FAILURE

    May 1, 2004, 00:00

  • PDB27 HOSPITALIZATIONS WITHIN THE VA AMONG VETERANS WITH DIABETES

    May 1, 2004, 00:00

  • PCN20 PRELIMINARY ECONOMIC ANALYSIS OF THE AMERICAN CANCER SOCIETY GUIDELINES FOR MAMMOGRAPHY SCREENING IN AVERAGE-RISK WOMEN UNDER 70 YEARS OF AGE

    May 1, 2004, 00:00

  • PCV16 DIFFERENCES IN RESOURCE UTILIZATION IN POST-MI PATIENTS WITH AND WITHOUT HEART FAILURE

    May 1, 2004, 00:00

  • PDB6 GENDER DISPARITY IN THE MANAGEMENT OF DYSLIPIDEMIA AMONG TYPE 2 DIABETES PATIENTS IN A MANAGED-CARE SETTING

    May 1, 2004, 00:00

  • PCV2 COMBINED LIPID GOAL ATTAINMENT IN THE MANAGED CARE SETTING

    May 1, 2004, 00:00

  • PMH73 DEPRESSION IN THE GENERAL POPULATION AND AFTER STROKE- A PSYCHOMETRIC COMPARISON USING THE CES-D SCALE

    May 1, 2004, 00:00

  • PMH54 WORK LOSS ASSOCIATED WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PNL20 UTILIZATION OF IMMUNOMODULATORY DRUG THERAPIES IN MULTIPLE SCLEROSIS (MS) IN NOVA SCOTIA, CANADA 1998-2003

    May 1, 2004, 00:00

  • PMD18 REAL-LIFE PATIENT REPORTED OUTCOMES- DATA MINING OF CONSUMER SPONTANEOUS REPORTS FOR TWO STATINS

    May 1, 2004, 00:00

  • PCN12 ECONOMIC BURDEN OF PANCREATIC CANCER AND TREATMENT FAILURE

    May 1, 2004, 00:00

  • PCV30 COST-EFFECTIVENESS OF STATINS IN CARDIOVASCULAR RISK MANAGEMENT- SYSTEMATIC REVIEW

    May 1, 2004, 00:00

  • PES8 ECONOMIC RESOURCES UTILIZED IN A COHORT OF PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD)

    May 1, 2004, 00:00

  • PAR6 COST-EFFECTIVENESS OF TREATMENT STRATEGIES FOR RHEUMATOID ARTHRITIS PATIENTS WITH INADEQUATE RESPONSE TO METHOTREXATE

    May 1, 2004, 00:00

  • PMD25 ELICITING WILLINGNESS TO PAY WITHIN THE HEALTH SECTOR WITHOUT BIAS

    May 1, 2004, 00:00

  • PAA19 CONSUMER SATISFACTION WITH ASTHMA TREATMENT-WHAT MATTERS?

    May 1, 2004, 00:00

  • PCV33 COST ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM FOR ANTI-OBESITY THERAPY IN A MEDICAID POPULATION

    May 1, 2004, 00:00

  • PCV35 VALIDATION OF THE EQ-5D QUESTIONNAIRE IN PATIENTS WITH A HISTORY OF ACUTE CORONARY SYNDROME

    May 1, 2004, 00:00

  • PDB8 THE ROLE OF INTRAOPERATIVE PARATHYROID HORMONE MONITORING FOR PARATHYROID HYPERPLASIA

    May 1, 2004, 00:00

  • PMH66 COMPARISON OF FIRST REFILL RATES AMONG BRANDED SSRI USERS

    May 1, 2004, 00:00

  • PIN26 MENINGOCOCCAL VACCINE IN PORTUGAL-A COST-EFFECTIVENESS ANALYSIS

    May 1, 2004, 00:00

  • PES14 MEDICATION AND HEALTH CARE SERVICE UTILIZATION RELATED TO DEPRESSIVE SYMPTOMS IN OLDER ADULTS WITH PSORIASIS

    May 1, 2004, 00:00

  • PAR13 BURDEN OF OSTEOARTHRITIS AND ITS TREATMENT ON PATIENTS

    May 1, 2004, 00:00

  • ND4 BURDEN OF ILLNESS IN ALZHEIMERS DISEASE IN THE UNITED KINGDOM

    May 1, 2004, 00:00

  • PAR14 CONTRIBUTION OF PAIN, SITE OF PAIN AND NUMBER OF JOINTS AFFECTED ON PRODUCTIVITY LOSS AMONG WORKERS AND NON-WORKERS WITH OSTEOARTHRITIS

    May 1, 2004, 00:00

  • SC1 COST EFFECTIVENESS OF SCREENING AND STATIN THERAPY IN CLINICAL GUIDELINES FOR CARDIOVASCULAR PROPHYLAXIS

    May 1, 2004, 00:00

  • PMD28 USING A WEB-PANEL TO AID DEFINITION OF A TARGET PATIENT POPULATION TO ASSIST RISK MANAGEMENT

    May 1, 2004, 00:00

  • PMH8 SWITCHING DISCONTINUATION OF SERTRALINE, PAROXETINE AND CITALOPRAM THERAPY

    May 1, 2004, 00:00

  • PNL3 PREDICTORS OF LOST PRODUCTIVITY AMONG EMPLOYEES WITH MIGRAINE HEADACHES IN A MEDICAL GROUP SETTING- IMPLICATIONS FOR WORKSITE DISEASE MANAGEMENT PROGRAMS

    May 1, 2004, 00:00

  • PMH16 OLANZAPINE VERSUS RISPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER- DETERMINANTS OF CHANGE IN SEVERITY OF BIPOLAR ILLNESS RATINGS

    May 1, 2004, 00:00

  • PCV38 HEALTH-RELATED QUALITY OF LIFE IN AN ACUTE CORONARY SYNDROME POPULATION IS AFFECTED BY DEPRESSION TREATMENT ADEQUACY

    May 1, 2004, 00:00

  • CV4 LOWER CARDIOVASCULAR RISK ASSOCIATED WITH PIOGLITAZONE MONOTHERAPY COMPARED TO INSULIN MONOTHERAPY- A RETROSPECTIVE PROPENSITY SCORE MATCHED COHORT STUDY

    May 1, 2004, 00:00

  • PCN19 THE COST-EFFECTIVENESS ANALYSIS RECOMBINANT HUMAN ERYTHROPOIETIN GROWTH FACTORS VS. TRANSFUSION IN CHEMOTHERAPY CANCER PATIENTS

    May 1, 2004, 00:00

  • PIN17 COST-EFFECTIVENESS MODELING OF TREATMENT APPROACHES TO HEPATITIS C- A MANAGED CARE PERSPECTIVE

    May 1, 2004, 00:00

  • PMD3 INCREMENTAL COST EFFECTIVENESS RATIOS AND CONFIDENCE INTERVALS-RELATIONSHIP OF CALCULATIONS WITH NNT VERSUS BOOTSTRAP METHODS

    May 1, 2004, 00:00

  • PHP38 AN ASSESSMENT OF THE EFFECT OF DEMOGRAPHICAL AND SOCIOLOGICAL FACTORS ON INDIVIDUAL RESPONSE TO DIRECT-TO-CONSUMER ADVERTISING OF PRESCRIPTION DRUGS

    May 1, 2004, 00:00

  • PES12 ESTIMATE OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE USE OF CONVENTIONAL SYSTEMIC AGENTS IN THE TREATMENT OF MODERATE TO SEVERE PSORIASIS

    May 1, 2004, 00:00

  • PMD8 HAZARD ISOBARS- A NEW, POLICY-ORIENTED TOOL FOR INTEGRATING INFORMATION FROM COX PROPORTIONAL HAZARD MODELS INTO COST-EFFECTIVENESS SIMULATIONS

    May 1, 2004, 00:00

  • PMH17 ANTIDEPRESSANT MONOTHERAPY AND OUTCOMES FOR PATIENTS WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PCV8 WARFARIN ANTICOAGULATION AND OUTCOMES IN ATRIAL FIBRILLATION PATIENTS-A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2004, 00:00

  • PMD12 MEDICATION COMPLIANCE AND CONCOMITANT THERAPY

    May 1, 2004, 00:00

  • PNL19 VALIDATION OF THE HUNTER SYNDROME-FUNCTIONAL OUTCOMES FOR CLINICAL UNDERSTANDING SCALE (HS-FOCUS)

    May 1, 2004, 00:00

  • PCV21 PREVALENCE AND COST IMPLICATIONS OF POTENTIAL INTERACTIONS WITH STATIN MEDICATIONS IN A MANAGED CARE POPULATION

    May 1, 2004, 00:00

  • PNL16 FACTORS THAT DETERMINE EMPLOYABILITY IN EPILEPSY PATIENTS- A PILOT STUDY

    May 1, 2004, 00:00

  • PAR11 REVALIDATION OF THE CEDARS-SINAI RHEUMATOID ARTHRITIS HEALTH-RELATED QUALITY OF LIFE (CSHQ-RA) SHORT FORM INSTRUMENT

    May 1, 2004, 00:00

  • PMD20 PRO INSTRUMENT DEVELOPMENT FOR RARE DISORDERS- A FOCUS-ED APPROACH

    May 1, 2004, 00:00

  • PDB9 POTENTIAL MEDICAL COST REDUCTION DUE TO DECREASES IN A1C RESULTING FROM PHARMACIST DIABETES EDUCATON AND MEDICATION RECOMMENDATIONS IN A COMMUNITY SETTING

    May 1, 2004, 00:00

  • PHP10 EQUITY IN THE NATIONAL HEALTH INSURANCE DURING ECONOMIC RECESSION- MISSION IMPOSSIBLE?

    May 1, 2004, 00:00

  • PMH42 CORRELATIONS BETWEEN PSYCHOPATHOLOGY AND HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN SCHIZOPHRENIA. RESULTS FROM THE SQUARE STUDY

    May 1, 2004, 00:00

  • PCV11 EVALUATING CLINICAL OUTCOMES FOR SUBJECTS THAT ARE NEWLY INITIATED ON HMG-COA REDUCTASE INHIBITORS IN A NATURALISTIC ENVIRONMENT USING LONGITUDINAL DESIGN

    May 1, 2004, 00:00

  • HP1 EVALUATION OF GENERIC DISPENSING INCENTIVE PROGRAM (GDIP)

    May 1, 2004, 00:00

  • PCV39 HEALTH STATUS IN HIGH-RISK PATIENTS UNDERGOING NONCARDIAC VASCULAR SURGERY IN THE UNITED STATES

    May 1, 2004, 00:00

  • PMH76 A COMPREHENSIVE RETROSPECTIVE STUDY OF ASSOCIATIONS BETWEEN DIABETES AND TREATMENT WITH RISPERIDONE, OLANZAPINE, QUETIAPINE, AND CONVENTIONAL ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • CN2 7215 COST-EFFECTIVENESS OF DIAGNOSTIC, STAGING, AND TREATMENT OPTIONS FOR MELANOMA

    May 1, 2004, 00:00

  • Abstracts Index

    May 1, 2004, 00:00

  • PMD13 ADHERENCE INDEX- A NEW AND IMPROVED APPROACH TO MEASURE MEDICATION COMPLIANCE

    May 1, 2004, 00:00

  • PAA11 EFFECTIVENESS AND COST-BENEFIT OF LEUKOTRIENE MODIFIERS IN ADULTS WITH ASTHMA IN THE OHIO MEDICAID POPULATION

    May 1, 2004, 00:00

  • PCN6 FACTORS INFLUENCING PHYSICIAN RECOMMENDATION FOR IMATINIB MESYLATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) PATIENTS

    May 1, 2004, 00:00

  • AC2 COMPARING PATIENT-REPORTED MEDICATION COMPLIANCE WITH ELECTRONICALLY MONITORED MEDICATION COMPLIANCE IN A 12-MONTH INTERNATIONAL REGISTRY

    May 1, 2004, 00:00

  • PNL11 HEALTH CARE COSTS FOR FLORIDA MEDICAID RECIPIENTS WITH MULTIPLE SCLEROSIS

    May 1, 2004, 00:00

  • PHP19 COMPARING THE COSTS OF MAIL ORDER AND RETAIL PHARMACY

    May 1, 2004, 00:00

  • PMH24 UTILIZATION ANALYSIS OF HEALTH CARE RESOURCES FOR PATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • CE3 THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE BREAST CANCER PATIENTS- COMPARISON OF ATTRIBUTABLE COST AND MICROCOSTING APPROACHES

    May 1, 2004, 00:00

  • PHP1 HOSPITALIZATIONS FOR INJURIES FROM FIREWORKS- RESOURCE USE AND COSTS

    May 1, 2004, 00:00

  • PNL6 COMPARISON OF CLINICAL EFFICACY AND COSTEFFECTIVENESS BETWEEN ELETRIPTAN 40MG AND SUMATRIPTAN 100MG IN THE ACUTE TREATMENT OF MIGRAINE

    May 1, 2004, 00:00

  • PCV42 PERSISTENCE AND ADHERENCE TO STATIN THERAPY IN A MANAGED CARE SETTING

    May 1, 2004, 00:00

  • PCN15 DIRECT MEDICAL COSTS OF MANAGING TOXICITIES RELATED TO TAXANE THERAPY FOR METASTATIC BREAST CANCER IN THE UNITED STATES

    May 1, 2004, 00:00

  • AC1 CAPTURING PATIENT-REPORTED COMPLIANCE DATA IN A NINE-COUNTRY PRODUCT REGISTRY USING MEMS CAP DEVICES

    May 1, 2004, 00:00

  • PHP17 RECENT TRENDS IN INPATIENT DRUG COSTS- 2000-2002

    May 1, 2004, 00:00

  • PIN12 COST-EFFECTIVENESS OF INTRAVENOUS IMMUNOGLOBULIN MANUFACTURED FROM CHROMOTOGRAPHY-CAPRYLATE VS. SOLVENT-DETERGENT METHODS IN PERSONS WITH PRIMARY IMMUNODEFICIENCY DISEASE

    May 1, 2004, 00:00

  • PCV57 ASSOCIATION BETWEEN INSURANCE COVERAGE AND OUTCOMES FOR INDIVIDUALS HOSPITALIZED FOR NONHEMORRHAGIC STROKE

    May 1, 2004, 00:00

  • PES1 PATIENTS PERSISTENCE AND ADHERENCE WITH GLAUCOMA THERAPY- A LONGITUDINAL RETROSPECTIVE DATABASE ANALYSIS OF OPHTHALMIC LIPIDS

    May 1, 2004, 00:00

  • PE1 ASSESSING EFFECTIVENESS IN THE PRESENCE OF TREATMENT SWITCHING- DATA FROM AN EFFECTIVENESS STUDY OF ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • PCN13 AN ECONOMIC ANALYSIS OF RADIATION VERSUS RADIATION PLUS GOSERELIN IN THE TREATMENT OF LOCALLY ADVANCED PROSTATE CANCER

    May 1, 2004, 00:00

  • PIN29 THE ECONOMIC EVALUATION OF INFLUENZA VACCINATION IN THE ELDERLY POPULATION- A MODEL BASED ON BAYESIAN NETWORKS

    May 1, 2004, 00:00

  • PCN7 TRENDS IN CHEMOTHERAPY USE, OUTCOMES, AND COST FOR PATIENTS WITH ADVANCED NONSMALL LUNG CANCER- EVIDENCE FROM SEER-MEDICARE

    May 1, 2004, 00:00

  • PHP28 PATIENT SATISFACTION-PATIENT EDUCATION INTERFACE

    May 1, 2004, 00:00

  • PDB26 PREFERENCE, EFFICACY, SAFETY AND ACTUAL USE OF BLOOD GLUCOSE (BG) MONITORING WITH INDUO VS SYRINGE AND SEPARATE METER IN SUBJECTS WITH TYPE 1 DIABETES

    May 1, 2004, 00:00

  • PCV24 7309 HEALTH CARE RESOURCE UTILIZATION BY PATIENTS WITH ESSENTIAL HYPERTENSION

    May 1, 2004, 00:00

  • PES7 A COST-EFFECTIVENESS ANALYSIS OF TREATING OPEN ANGLE GLAUCOMA

    May 1, 2004, 00:00

  • PMH71 WHEN BIPOLAR DISORDER IS BEING IDENTIFIED- PHASE OF DISORDER, PROVIDER SPECIALTY, FACILITY TYPE, AND RESOURCE UTILIZATION SURROUNDING THE INITIAL BIPOLAR DIAGNOSIS IN CLINICAL PRACTICE

    May 1, 2004, 00:00

  • PCV29 COST EFFECTIVENESS ANALYSIS OF THERAPY MODIFICATION AFTER FAILING STATIN TREATMENT

    May 1, 2004, 00:00

  • PAA2 THE PREVALENCE OF INAPPROPRIATE USE OF SHORTACTING ASTHMA MEDICATION

    May 1, 2004, 00:00

  • PMH19 ESCITALOPRAM IN THE TREATMENT OF KLEPTOMANIA

    May 1, 2004, 00:00

  • PAA7 HEALTH CARE EXPENDITURES OF PATIENTS WITH COMORBID ALLERGIC RHINITIS AND ASTHMA

    May 1, 2004, 00:00

  • PES2 MEDICATION ADHERENCE RATES AND DISEASE SEVERITY CHANGES IN PSORIASIS

    May 1, 2004, 00:00

  • PMH7 TREATMENT AND ECONOMIC OUTCOMES IN PEDIATRIC INPATIENTS TREATED WITH ATYPICAL ANTIPSYCHOTICS

    May 1, 2004, 00:00

  • PIN1 OUTCOMES OF AN INTERACTIVE VOICE RESPONSE (IVR) REMINDER SYSTEM TO PROMOTE MANAGED CARE ORGANIZATION (MCO) MEMBERS ATTAINMENT OF INFLUENZA IMMUNIZATION

    May 1, 2004, 00:00

  • PMH13 USING PATIENT REPORTED OUTCOMES (PROS) TO DETERMINE DEPRESSION AND ANXIETY POPULATIONS IN FOUR COUNTRIES

    May 1, 2004, 00:00

  • PIN27 THE IMPACT OF PHYSICIAN PROFILING ON ANTIBIOTIC COST AND UTILIZATION

    May 1, 2004, 00:00

  • PCV6 ANALYZING RISK OF BLEEDING IN ADMINISTERING LOW MOLECULAR WEIGHT HEPARINS AND/OR ASPIRIN TO ORTHOPEDIC PATIENTS

    May 1, 2004, 00:00

  • PMD11 CHOOSING AMONG DIFFERENT TYPES OF BOOTSTRAPPING METHODS

    May 1, 2004, 00:00

  • PCV50 GASTRIC BYPASS SURGERY-AN OVERVIEW

    May 1, 2004, 00:00

  • PIN30 OBSERVATIONAL STUDY ON THE 'REAL LIFE' PRACTICE AND COST OF ANTIBIOTIC (AB) MEDICATION IN PNEUMOCOCCAL PNEUMONIA PATIENTS- PARENTERAL VERSUS STEP DOWN THERAPY (SDT)

    May 1, 2004, 00:00

  • PCV1 ZIPRASIDONE VS OLANZAPINE- CONTRASTS IN CHD RISK- PCVI

    May 1, 2004, 00:00

  • PBR5 GREATER AREA UNDER THE HEMOGLOBIN CHANGE CURVE DURING EPOETIN ALFA TREATMENT IS ASSOCIATED WITH IMPROVED PATIENT OUTCOMES

    May 1, 2004, 00:00

  • PNL1 HOW COGNITIVE FUNCTION AFFECTS ACTIVITIES OF DAILY LIVING IN PATIENTS WITH ALZHEIMERS DISEASE

    May 1, 2004, 00:00

  • PAA10 BUDGET IMPACT ANALYSIS- COMBINATION FLUTICASONE AND SALMETEROL FOR ASTHMA

    May 1, 2004, 00:00

  • RX3 EVALUATING CLINICAL AND FINANCIAL OUTCOMES ASSOCIATED WITH A RETROSPECTIVE DRUG UTILIZATION REVIEW PROGRAM

    May 1, 2004, 00:00

  • PAR15 ETHNIC VARIATIONS IN PREFERENCE FOR TOTAL KNEE REPLACEMENT IN PATIENTS WITH OSTEOARTHRITIS

    May 1, 2004, 00:00

  • PDB12 ESTIMATING THE REDUCTION IN LONG TERM COMPLICATION AND COSTS OF COMPLICATIONS IN TYPE 1 DIABETES BY REDUCED A1C LEVELS DUE TO MORE FREQUENT BLOOD GLUCOSE MONITORING

    May 1, 2004, 00:00

  • MH4 ASSESSMENT OF HEALTH STATE UTILITIES FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN CHILDREN USING PARENT-BASED STANDARD GAMBL SCORES

    May 1, 2004, 00:00

  • PNL2 OXCARBAZEPINE REDUCES HOSPITALISATIONS FOR EPILEPTIC SEIZURES AND RELATED SYMPTOMS IN THE NETHERLANDS- A PHARMO STUDY

    May 1, 2004, 00:00

  • PGI11 RETROSPECTIVE ANALYSIS OF A PRIOR AUTHORIZATION PROGRAM USING COX-2 INHIBITORS IN A MANAGED CARE POPULATION

    May 1, 2004, 00:00

  • PNL7 A RETROSPECTIVE CLAIMS ANALYSIS OF THE DIRECT COSTS OF MIGRAINE AND ITS COMORBID CONDITIONS IN TAIWAN

    May 1, 2004, 00:00

  • PHP42 METHODS FOR 'GO/NO-GO' MODELING OF COMPOUNDS IN THE DEVELOPMENT PIPELINE

    May 1, 2004, 00:00

  • PMH48 ASSESSMENT OF THE IMPACT OF QUETIAPINE TREATMENT ON PSYCHOPATHOLOGY, HEALTH RELATED QUALITY OF LIFE AND DISABILITY IN PATIENTS WITH SCHIZOPHRENIA IN GREECE.THE SQUARE STUDY

    May 1, 2004, 00:00

  • PAR16 TRENDS IN THE USE OF PATIENT REPORTED OUTCOMES IN OSTEOARTHRITIS CLINICAL TRIALS AND SUBSEQUENT PRODUCT LABELS

    May 1, 2004, 00:00

  • PHP11 ESTIMATING THE ABILITY-TO-PAY FOR HEALTH CARE EXPENDITURES RISING FASTER THAN GDP- AN INTERNATIONAL PERSPECTIVE COMPARING THE USA AND GERMANY

    May 1, 2004, 00:00

  • PCN10 THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR BASAL CELL CARCINOMA

    May 1, 2004, 00:00

  • PES4 COST-UTILITY OF COCHLEAR IMPLANTS A SOCIETAL PERSPECTIVE ANALYSIS

    May 1, 2004, 00:00

  • PAR5 COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRATM) IN THE TREATMENT OF US PATIENTS WITH RHEUMATOID ARTHRITIS (RA)

    May 1, 2004, 00:00

  • PES9 ELIGIBILITY, UTILIZATION, AND COSTS IN A CALIFORNIA MEDICAID LUPUS POPULATION

    May 1, 2004, 00:00

  • PMD17 USING AN ARTIFICIAL NEURAL NETWORK TO PREDICT UTILITY SCORES FROM SF-36 DATA

    May 1, 2004, 00:00

  • PIN6 TAMPON-RELATED TOXIC SHOCK SYNDROME (TSS) CONTINUES TO PEAK AMONG ADOLESCENT GIRLS- A NATIONWIDE HOSPITAL STUDY

    May 1, 2004, 00:00

  • PPN2 THE DIRECT AND INDIRECT ECONOMIC IMPACT OF PAIN AND ITS COMPARISON WITH THREE OF THE TOP FIVE MOST COSTLY DISEASES

    May 1, 2004, 00:00

  • PHP27 INFLATION- PRESCRIPTION DRUG MARKET BASKET DEFINITION AND THEIR IMPACT

    May 1, 2004, 00:00

  • PHP24 QUALITY OF DECISION-MAKING BY THE PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE (PBAC) AND THE IMPACT ON OUTCOMES

    May 1, 2004, 00:00

  • PCV7 EFFECTIVENESS OF LIPID-LOWERING THERAPY IN PRIMARY CARE IN FRANCE

    May 1, 2004, 00:00

  • PCN18 COST ANALYSIS OF LUNG CANCER TREATMENT IN TAIWAN

    May 1, 2004, 00:00

  • PGI2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF TOTAL AND PARTIAL LAPAROSCOPIC FUNDOPLICATION FOR THE TREATMENT OF GORD

    May 1, 2004, 00:00

  • PIN5 A META-ANALYSIS OF THREE-DAY AZITHROMYCIN THERAPY VERSUS LONGER COURSES OF COMPARATOR ANTIBIOTICS IN ACUTE SINUSITIS

    May 1, 2004, 00:00

  • CV3 THE USE OF A PROBABILISTIC DECISION MODEL TO ASSESS THE COST-EFFECTIVENESS OF DRUG-ELUTING STENTS IN ALTERNATIVE PATIENT SUB-GROUPS

    May 1, 2004, 00:00

  • PCV28 AN ARB COST-EFFECTIVENESS MODEL IN TREATING MILD-TO-MODERATE HYPERTENSION

    May 1, 2004, 00:00

  • PMH69 PATTERNS OF PHARMACOLOGIC TREATMENT FOR PATIENTS WITH BIPOLAR DISORDER

    May 1, 2004, 00:00

  • PCV51 RETROSPECTIVE EVALUATION OF UTILIZATION PATTERNS OF BETA-BLOCKER THERAPY IN CONGESTIVE HEART FAILURE PATIENTS IN A MANAGED CARE ENVIRONMENT

    May 1, 2004, 00:00

  • PCN11 COST-EFFECTIVENESS ANALYSIS OF DOSE-DENSE CHEMOTHERAPY WITH FILGRASTIM AS POSTOPERATIVE ADJUVANT TREATMENT OF BREAST CANCER

    May 1, 2004, 00:00

  • PDB16 THE ECONOMIC AND HEALTH OUTCOMES OF USING DIFFERENT INSULIN DELIVERY DEVICES IN A MANAGED CARE ENVIRONMENT

    May 1, 2004, 00:00

  • PNL22 THE SENSITIVITY OF COST-EFFECTIVENESS ESTIMATES IN MULTIPLE SCLEROSIS TO INTERNATIONAL DIFFERENCES IN NATURAL HISTORY- SWEDEN VERSUS NOVA SCOTIA, CANADA

    May 1, 2004, 00:00

  • PDB22 THE VALUE TO HIGH-RISK PATIENTS OF PREVENTING A CASE OF DIABETES

    May 1, 2004, 00:00

  • PIN4 EXAMINATION OF HEPATITIS C IN THE LOUISIANA MEDICAID POPULATION

    May 1, 2004, 00:00

  • PES10 THE COST-EFFECTIVENESS OF METHYL AMINOLEVULINATE PHOTODYNAMIC THERAPY (MAL-PDT) FOR DIFFICULT TO TREAT ACTINIC KERATOSES

    May 1, 2004, 00:00

  • OP2 COMPARISON OF DISCRETE CHOICE EXPERIMENT (DCE) WITH VISUAL ANALOG SCALING (VAS) METHODS FOR ESTIMATING PREFERENCES FOR PHYSICAL DISABILITY STATES

    May 1, 2004, 00:00

  • PCN2 IMPACT OF CHEMOTHERAPY-INDUCED DIARRHEA ON MANAGEMENT PATTERNS AND RESOURCE UTILIZATION AMONG CANCER PATIENTS- RESULTS FROM A MULTI-SITE STUDY

    May 1, 2004, 00:00

  • PPN9 PRESCRIPTION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND MUSCLE RELAXANTS FOR BACK PAIN IN THE UNITED STATES

    May 1, 2004, 00:00

  • PCV31 ECONOMIC ANALYSIS OF AMIODARONE, ATRIAL SEPTAL PA CING, AMIODARONE PLUS ATRIAL SEPTAL PACING VERSUS STANDARD OF CARE TO PREVENT ATRIAL FIBRILLATION AFTER OPEN-HEART SURGERY

    May 1, 2004, 00:00

  • PCN27 THE BREAST CANCER SCREENING RATES OF GEORGIA MEDICAID RECIPIENTS

    May 1, 2004, 00:00

  • PHP15 INCLUDING CARER UTILITY IN ECONOMIC EVALUATIONS- A PRELIMINARY ANALYSIS OF THE IMPLICATIONS FOR FUNDING THRESHOLDS

    May 1, 2004, 00:00

  • PCN4 TECHNOLOGY ADVANCES AND TREATMENT PATTERN VARIATIONS IN ONCOLOGY- EVIDENCE FROM USE OF CPT-11 IN ELDERLY METASTATIC COLORECTAL CANCER PATIENTS

    May 1, 2004, 00:00

  • PIN34 THE USE OF ANTIBIOTICS TO TREAT ACUTE UPPER RESPIRATORY TRACT INFECTIONS IN A STATE MEDICAID POPULATION

    May 1, 2004, 00:00

  • ND1 ESTIMATING COST-EFFECTIVENESS OF DRUGS THAT DELAY DISABILITY PROGRESSION IN MULTIPLE SCLEROSIS USING NET BENEFIT REGRESSION MODEL METHODS

    May 1, 2004, 00:00

  • PUK9 ECONOMIC IMPACT OF EPOETIN ALFA (EPO) TREATMENT AMONG NON-DIALYSIS CHRONIC KIDNEY DISEASE (NDCKD) PATIENTS WITH ANEMIA

    May 1, 2004, 00:00

  • PMH43 DIFFERENTIAL IMPACT OF OLANZAPINE AND RISPERIDONE ON SEXUAL DYSFUNCTION AND ITS POTENTIAL IMPLICATIONS

    May 1, 2004, 00:00

  • PNL13 A COMPARATIVE COST ANALYSIS OF VASCULAR DEMENTIA VERSUS ALZHEIMERS DISEASE IN TAIWAN

    May 1, 2004, 00:00

  • PMH67 DEPRESSION DIAGNOSIS IN PRIMARY CARE VISITS NOT FOR MENTAL HEALTH REASONS

    May 1, 2004, 00:00

  • POS1 THE INFLUENCE OF BONE MINERAL DENSITY TESTING ON THE INITIATION OF AN OSTEOPOROSIS-RELATED PHARMACOTHERAPY- A POPULATION-BASED ANALYSIS

    May 1, 2004, 00:00

  • PMH37 COST CONSEQUENCE ASSOCIATED WITH DIFFERENT INITIAL MOOD STABILIZERS FOR NEWLY TREATED PATIENTS WITH BIPOLAR DISORDERS

    May 1, 2004, 00:00

  • PCV12 UTILIZATION PATTERNS OF HYPERTENSION THERAPIES AMONG PATIENTS INITIATING ANGIOTENSION II RECEPTOR ANTAGONIST THERAPY

    May 1, 2004, 00:00

  • POS2 DIFFERENCES BETWEEN DOCTOR AND PATIENT RECALL OF EVENTS IN AND INVESTIGATIONS FOR OSTEOPOROSIS IN FIVE COUNTRIES

    May 1, 2004, 00:00

  • PPN3 AN EVALUATION OF THE DIRECT COSTS OF ADVERSE GI EVENTS ASSOCIATED WITH THE USE OF NSAIDS IN THE UNITED STATES

    May 1, 2004, 00:00

  • PMH77 ORDERING EFFECTS IN CROSSOVER STUDIES OF PHOTOTHERAPY- IMPLICATIONS FOR PSYCHOLOGICAL INTERVENTIONS

    May 1, 2004, 00:00

  • PMD23 WHAT IS THE VALUE OF SOCIAL VALUES? THE USELESSNESS OF ASSESSING HEALTH-RELATED QUALITY OF LIFE THROUGH PREFERENCE MEASURES

    May 1, 2004, 00:00

  • PDB11 DIFFERENCES IN HYPOGLYCEMIA EVENT RATES AND ASSOCIATED COST-CONSEQUENCE IN PATIENTS INITIATED ON LONG-ACTING AND INTERMEDIATE-ACTING INSULIN PRODUCTS

    May 1, 2004, 00:00

  • PUK3 DITROPAN XL PROVIDES SUPERIOR OUTCOMES AND LOWER COSTS COMPARED TO DETROL LA

    May 1, 2004, 00:00

  • PGI3 COST-UTILITY ANALYSIS COMPARING ESOMEPRAZOLE WITH THE ORO-DISPERSIBLE FORMULATION OF LANSOPRAZOLE IN THE INITIAL TREATMENT OF REFLUX OESOPHAGITIS

    May 1, 2004, 00:00

  • PCV47 THE NATIONAL ANTICOAGULATION BENCHMARK AND OUTCOMES REPORT (NABORTM)- EVIDENCE OF A SIGNIFICANT DIFFERENCE BETWEEN GUIDELINES AND ACTUAL PRACTICE

    May 1, 2004, 00:00

  • PCV32 USE OF ANTILIPEMIC DRUGS IN NATIONAL HEALTH CARE GROUP (NHG), SINGAPORE

    May 1, 2004, 00:00

  • PMH20 RISK OF REHOSPITALIZATION- OLANZAPINE VERSUS QUETIAPINE

    May 1, 2004, 00:00

  • PCV22 COST AND COMORBIDITIES ASSOCIATED WITH ATRIAL FIBRILLATION IN DIFFERENT AGE GROUPS

    May 1, 2004, 00:00

  • POS6 TERIPARATIDE VERSUS BISPHOSPHONATES IN HIGH RISK OSTEOPOROSIS PATIENTS- A DECISION MODEL ANALYSIS

    May 1, 2004, 00:00

  • PAA18 THE ASSOCIATION BETWEEN MEASURES OF HEALTH STATE UTILITIES, QUALITY OF LIFE AND WILLINGNESS TO PAY IN ASTHMA

    May 1, 2004, 00:00

  • DB3 OUTCOMES ASSOCIATED WITH THE INTRODUCTION OF THIAZOLIDINEDIONE THERAPY IN ELDERLY PATIENTS WITH TYPE 2 DIABETES MELLITUS- A RETROSPECTIVE DATA ANALYSIS

    May 1, 2004, 00:00

  • PGI7 FECAL LACTOFERRIN ASSAY FOR THE INITIAL DIAGNOSTIC APPROACH TO SYMPTOMATIC PATIENTS WITH ILEAL POUCH-ANAL ANASTOMOSIS-A COST-EFFECTIVENESS ANALYSIS

    May 1, 2004, 00:00

  • PMH27 DIRECT HEALTH CARE COST OF DEPRESSIVE DISORDERSIN THE UNITED STATES- A PATIENT TIME PROFILE

    May 1, 2004, 00:00

  • PMD2 MONTE-CARLO VALIDATION OF DELTA-K METHOD FOR SAMPLE-SIZE CALCULATION IN A COST-EFFECTIVENESS TRIAL

    May 1, 2004, 00:00

  • PBR4 BLOOD DONATION IN THE 21ST CENTURY- MOTIVATION AMIDST CRISIS

    May 1, 2004, 00:00

  • PMH79 STATISTICALLY DETERMINING TREATMENT OF CHOICE FOR INDIVIDUAL PATIENTS WITH SCHIZOPHRENIA

    May 1, 2004, 00:00

  • PDB15 TOTAL CHOLESTEROL, HDL CHOLESTEROL AND HBA1C AFFECT QUALITY-ADJUSTED LIFE YEARS AND HOSPITAL COSTS FOR PATIENTS WITH TYPE 2 DIABETES IN THE UNITED KINGDOM-THE CARDIFF DIABETES COST UTILITY MODEL

    May 1, 2004, 00:00

  • PGI5 COST-EFFECTIVENESS OF TREATING ADULTS WITH CHRONIC HEPATITIS C (CHC) AND PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE (PNALT) WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS)

    May 1, 2004, 00:00

  • PIN9 VARIABILITY IN THE USE OF HIV PHENOTYPIC TESTING BY SPECIALTY OF PRACTITIONER

    May 1, 2004, 00:00

  • PMH58 THE RELATIONSHIP BETWEEN MENTAL DISTRESS, HEALTH RISKS AND HEALTH CARE COSTS FROM THE MANAGED CARE HEALTH RISK ASSESSMENT DATABASE

    May 1, 2004, 00:00

  • PCN31 WEIGHT OR NOT TO WEIGHT?

    May 1, 2004, 00:00

  • PMH28 COST-EFFECTIVENESS OF INTERVENTIONS TO IMPROVE PATIENT MEDICATON COMPLIANCE IN MAJOR DEPRESSIVE DISORDER

    May 1, 2004, 00:00

  • PNL14 HEALTH CARE UTILIZATION AND EXPENDITURES AMONG MEDICAID PATIENTS WITH PARKINSONS DISEASE

    May 1, 2004, 00:00

  • PUK12 PROSPECTIVE URINARY INCONTINENCE RESEARCH (PURE)- DESCRIPTION OF STUDY, RATIONAL, DESIGN AND METHODOLOGY

    May 1, 2004, 00:00

  • PMH45 MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALE

    May 1, 2004, 00:00

  • PHP30 PATIENT SATISFACTION WITH HEALTH CARE SERVICES- IDENTIFYING VOIDS

    May 1, 2004, 00:00

  • PES6 PATIENT-REPORTED IMPACT OF AGE-RELATED MACULAR DEGENERATION

    May 1, 2004, 00:00

  • PPN8 PATTERNS AND TRENDS IN OPIOID USE AMONG INDIVIDUALS WITH BACK PAIN IN THE UNITED STATES

    May 1, 2004, 00:00
  • «
  • 171 (current)
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • »